Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
3(23%)
Results Posted
40%(2 trials)
Terminated
3(23%)

Phase Distribution

Ph early_phase_1
1
8%
Ph phase_2
4
31%
Ph phase_1
4
31%
Ph not_applicable
4
31%

Phase Distribution

5

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
4(30.8%)
N/ANon-phased studies
4(30.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(5)
Terminated(4)
Other(1)

Detailed Status

Completed5
Terminated3
Recruiting3
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
62.5%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (7.7%)
Phase 14 (30.8%)
Phase 24 (30.8%)
N/A4 (30.8%)

Trials by Status

terminated323%
recruiting323%
withdrawn18%
unknown18%
completed538%

Recent Activity

3 active trials
Showing 5 of 13
recruitingearly_phase_1

Researching Economical Adjuvants to Cancer Therapy

NCT07305259
completedphase_2

Beta-glucan and Immune Response to Influenza Vaccine

NCT05074303
recruitingnot_applicable

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

NCT04513028
recruitingnot_applicable

The Effect of Beta-glucan in Non-Small Cell Lung Cancer

NCT00682032
terminatedphase_1

Beta-glucan and Fatigue in HSCT Survivors

NCT05524688
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07305259Early Phase 1

Researching Economical Adjuvants to Cancer Therapy

Recruiting
NCT05074303Phase 2

Beta-glucan and Immune Response to Influenza Vaccine

Completed
NCT04513028Not Applicable

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Recruiting
NCT00682032Not Applicable

The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Recruiting
NCT05524688Phase 1

Beta-glucan and Fatigue in HSCT Survivors

Terminated
NCT00492167Phase 1

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Completed
NCT04114513Not Applicable

Dietary Fibers Effect on the Gut Microbiota Composition

Withdrawn
NCT03769012Not Applicable

Ability of Beta-glucan Supplementation to Augment Immune Function

Completed
NCT04710290Phase 2

A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers

Unknown
NCT00290407Phase 2

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

Terminated
NCT00087009Phase 1

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Terminated
NCT00037011Phase 1

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Completed
NCT00089258Phase 2

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Completed

All 13 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
13